Sandeep Gurbuxani to Myeloproliferative Disorders
This is a "connection" page, showing publications Sandeep Gurbuxani has written about Myeloproliferative Disorders.
Connection Strength
2.574
-
SETBP1 sets the stage. Blood. 2024 Apr 04; 143(14):1323-1324.
Score: 0.849
-
The Times, They Are A-Changing: The Impact of Next-Generation Sequencing on Diagnosis, Classification, and Prognostication of Myeloid Malignancies With Focus on Myelodysplastic Syndrome, AML, and Germline Predisposition. Am Soc Clin Oncol Educ Book. 2023 Jun; 43:e390026.
Score: 0.801
-
IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood. 2022 12 29; 140(26):2805-2817.
Score: 0.194
-
Type I but Not Type II Calreticulin Mutations Activate the IRE1a/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms. Blood Cancer Discov. 2022 07 06; 3(4):298-315.
Score: 0.188
-
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
Score: 0.162
-
A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk Lymphoma. 2014 Dec; 55(12):2945-6.
Score: 0.106
-
AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia. 2013 Sep; 27(9):1882-90.
Score: 0.100
-
Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood. 2008 Jan 15; 111(2):767-75.
Score: 0.068
-
Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells Mol Dis. 2003 Nov-Dec; 31(3):351-6.
Score: 0.052
-
LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms. Cancer Discov. 2021 06; 11(6):1398-1410.
Score: 0.043
-
Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003 Jun 01; 101(11):4298-300.
Score: 0.012